Pramipexole, sold under the brand Mirapex among others, is medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS). In Parkinson's disease it may be used alone or together with levodopa. It is taken by mouth. Pramipexole is a dopamine agonist of the non-ergoline class.
Mogens Schou was a Danish psychiatrist whose research into lithium led to its utilization as a treatment for bipolar disorder.
Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City, and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease. His research led to four of the first five FDA-approved drugs for Alzheimer's.
Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.
Guy Goodwin is a senior research fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He is also an Emeritus Senior Investigator at the National Institute for Health and Care Research (NIHR) and has been on the advisory boards of numerous research councils. He was President of the European College of Neuropsychopharmacology from 2013 to 2016.
Jules Angst is a Swiss academic who is Emeritus Professor of Psychiatry at Zurich University in Zurich, Switzerland, and Honorary Doctor of Heidelberg University in Heidelberg, Germany.
The European College of Neuropsychopharmacology (ECNP) is a pan-European, non-profit scientific association that serves as a platform to exchange and promote research in the field of neuropsychopharmacology. The ECNP “is committed to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health”. The ECNP organises a number of activities to achieve this aim, such as a yearly congress, workshops, seminars, New Frontiers Meetings, publications, awards, supported talks and much more.
Julio Vallejo Ruiloba was a Spanish psychiatrist, medical doctor, Chairman of the Psychiatry Department at the Universitat de Barcelona, ex-President of the Spanish Psychiatry Society, and Academician of the Royal Academy of Medicine of Catalonia. He wrote 56 books about psychiatry and more than 350 scientific papers.
Celso Arango is a psychiatrist who has worked as a clinician, researcher, and educator in psychiatry and mental health, notably in the field of child and adolescent psychiatry, psychosis, and mental health promotion.
Wim van den Brink is emeritus Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam. He was Director of the Amsterdam Institute for Addiction Research (AIAR) and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.
Joseph Zohar is the director of Psychiatry and the Anxiety and Obsessive Compulsive Clinic at the Sheba Medical Center in Tel HaShomer and professor of psychiatry at Tel Aviv University, Israel. He is the founder of the World Council on Anxiety as well as the Israeli Consortium on PTSD. He currently leads the chief installation of the Israeli Defense Force for the treatment of PTSD. He is a member of the executive committee of the European College of Neuropsychopharmacology, of which he is a former president, and chairman of the Expert Platform on Mental Health.
Elisabeth Binder is a medical doctor and neuroscientist specializing in the study of mood and anxiety disorders. She is the director of the Department of Translational Research of the Max Planck Institute of Psychiatry in Munich, Germany. In addition to research, she is a member of the executive committee of the European College of Neuropsychopharmacology (ECNP).
Laurence Lanfumey-Mongredien is a neuroscientist specializing in preclinical research in neuroscience and molecular neuropsychopharmacology. Based at INSERM, she is the team leader of the “Pathophysiology of anxio-depressive and addictive disorders” research group. She is also a member of many scientific communities, most notably serving as a councilor on the executive committee of the European College of Neuropsychopharmacology.
Salomon Zender Langer is an Argentinian pharmacologist whose family had fled from Poland to Argentina in the early 1930s and were thus saved from the Holocaust during the Second World War.
Walter Wolfgang Fleischhacker is an Austrian psychiatrist and psychotherapist. Previously professor of psychiatry at the Medical University Innsbruck, he was appointed president of the university on 1 October 2017.
Prof. Robert Haim Belmaker, is an Israeli psychiatrist who has had major academic positions in Israeli psychiatry since 1974. He had a formative influence on biological directions in Israeli psychiatry. He was Hoffer-Vickar Professor of Psychiatry at Ben-Gurion University of the Negev, Beersheva Israel until his retirement and is now Emeritus.
René Sylvain Kahn is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017. He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.
Mauricio Tohen is a Mexican American research psychiatrist, Distinguished Professor, and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico. Tohen's research has focused on the epidemiology, outcome, and treatment of bipolar and psychotic disorders, and is especially known for innovating the design of clinical trials and the criteria to determine outcome in such diseases. Tohen has edited several books on his specialties. His social awareness has been noted in the promotion of programs to improve mental health care in areas such as substance abuse, bipolar disorder and schizophrenia.
Ross J. Baldessarini, a psychopharmacologist, is the Director, International Consortium for Bipolar & Psychotic Disorders Research at McLean Hospital and Professor of Psychiatry (Neuroscience) at Harvard Medical School.
Gabriella Gobbi is an Italo-Canadian psychiatrist and neuroscientist whose research explores novel treatments for mental health disorders. Gobbi is a professor at McGill University's Department of Psychiatry and a Canada Research Chair in Therapeutics for Mental Health.
